Author

Jan Fagerberg

Observed names: J Fagerberg, J. Fagerberg

OpenAlex ID: A5029670685

EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.

2022 · Wolfgang Wick, Ahmed Idbaih, et al. · Journal of Clinical Oncology · 7

2MO EO2401 (EO) therapeutic vaccine for patients (pts) with adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP): Phase I/II SPENCER study

2022 · E. Baudin, S. Grisanti, et al. · Annals of Oncology · 4

Ctim-25. Eo2401 Peptide Immunotherapy + Nivolumab +/- Bevacizumab in First Recurrent Glioblastoma: the Phase 1/2 Eogbm1-18/rosalie Study (nct04116658)

2023 · David Reardon, Ahmed Idbaih, et al. · Neuro-Oncology · 3

PDF

Ctim-17. Eo2401 Therapeutic Vaccine for Patients With Recurrent Glioblastoma: Phase 1/2 Rosalie Study (nct04116658)

2022 · David A Reardon, Ahmed Idbaih, et al. · Neuro-Oncology · 3

PDF

724O EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER

2023 · E. Baudin, S. Grisanti, et al. · Annals of Oncology · 2

PDF

Ctim-15. Eo2401 Peptide Immunotherapy + Nivolumab +/- Bevacizumab in First Recurrent Glioblastoma: Treatment Strategy Optimization in the Phase 1/2 Study Eogbm1-18 / Rosalie (nct04116658)

2025 · David A Reardon, Ahmed Idbaih, et al. · Neuro-Oncology · 1

PDF

162P EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)

2024 · R. Cohen, M.E. Elez Fernandez, et al. · Immuno-Oncology Technology · 1

PDF

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

2024 · Jose C. Villasboas Bisneto, Stephen D. Smith, et al. · Blood · 1

PDF

Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).

2024 · Jose Caetano Villasboas, Danielle Wallace, et al. · Journal of Clinical Oncology · 1

EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.

2023 · Wolfgang Wick, Ahmed Idbaih, et al. · Journal of Clinical Oncology · 1

170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study

2022 · W. Wick, A. IdBaih, et al. · Immuno-Oncology Technology · 1

PDF

A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).

2022 · Pier Luigi Zinzani, Stephen M. Ansell, et al. · Journal of Clinical Oncology · 1

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

2025 · Stephen Smith, Francesc Bosch Albareda, et al. · Blood

PDF

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

2024 · Jose C. Villasboas Bisneto, Danielle S Wallace, et al. · Blood

PDF

Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY

2023 · A. A. Pinto, F. Bosch, et al. · Hematological Oncology

PDF

PL02.1.A EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study

2022 · A Idbaih, M Vieito, et al. · Neuro-Oncology

PDF

303P EO2401 (EO) therapeutic vaccine for patients (pts) with recurrent glioblastoma (GB): Phase I/II ROSALIE study

2022 · D.A. Reardon, A. Idbaih, et al. · Annals of Oncology

PDF

P1115: a Multicenter Phase 1/2 Trial of Eo2463, a Microbial-derived Peptide Therapeutic Vaccine, as Monotherapy and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Nhl

2022 · P. L. Zinzani, S. M. Ansell, et al. · HemaSphere

Works count: 18

Citation count: 26

H-index: 3

I10-index: